Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis
Rohit Loomba,Mark L Hartman,Eric J Lawitz,Raj Vuppalanchi,Jérôme Boursier,Elisabetta Bugianesi,Masato Yoneda,Cynthia Behling,Oscar W Cummings,Yuanyuan Tang,Bram Brouwers,Deborah A Robins,Amir Nikooie,Mathijs C Bunck,Axel Haupt,Arun J Sanyal,SYNERGY-NASH Investigators,Christophe De Block,Charlotte De Vloo,Hendrik Reynaert,Ann Mertens,Anja Geerts,Christophe Bureau,Lionel Wander,Vlad Ratziu,Victor De Ledinhgen,Cyrielle Caussy,Marie Lequoy,Armelle Poujol Robert,Eli Zuckerman,Ella Veitsman,Rifaat Safadi,Ziv Ben-Ari,Gadi Lalazar,Nimer Assy,Emanuela Orsi,Gaetano Serviddio,Salvatore Petta,Palermo Palermo,Luca Miele,Frida Leonetti,Kazuo Notsumata,Yasuhiro Asahina,Yuji Ogawa,Yokohama Yoshiyuki Ueno,Shigetoshi Fujiyama,Toshihide Shima,Hirokazu Takahashi,Saga Hiroshi Tobita,Hideki Hayashi,Takeshi Yokoo,Masahiro Kido,Masashi Yoneda,Ken Furuya,Saiyu Tanaka,Yoshito Itoh,Hideki Fujii,Alma Laura Ladron de Guevara,Jorge Rojas Serrano,Enrique Fernandez Castro,Eduardo Mendoza Fuerte,Marcin Ojrzanowski,Ewa Czernecka,Santiago Tofe Povedano,Luis de Teresa Parreño,Javier Garcia de Paso Mora,Manuel Romero Gomez,Javier Crespo Garcia,Jose Luis Calleja Panero,Agustin Albillos,Shalini Iyengar,Carol Pretswell,Madhu Gowda,Karen Faulkner,Kosh Agarwal,William Alazawi,Cyril Sieberhagen,Pinelopi Manousou,Stephen Ryder,Jeremy Cobbold,Matthew Armstrong,Daniel Forton,Seth Baum,Juan Pablo Frias,David Guzman,Stanley Hsia,Julio Rosenstock,Kathryn Jean Lucas,Andrew Talal,Ajay Chaudhuri,Susan Brian,Tira Chaicha-Brom,Anuj Bhargava,Gholamreza Bonabi,Mark Borchelt,Michele Reynolds,Sherif Naguib,Rizwana Mohseni,Hernan Salazar,Thomas Klein,Richard Glover,John Scott,Eva-Maria Heurich,Hesham Elgouhari,Syed Lateef,Zeid Kayali,Gary Reiss,Brian Borg,Muhammad Sheikh,Howard Schwartz,Meagan Gray,Charles Landis,Ira Jacobson,Henry Levine,Meena Bansal,Amreen Dinani,Amon Asgharpour,Eric Lawitz,Samuel Sigal,Abdullah Mubarak,Mark Leibowitz,Randall Severance,Jewel White,William Jennings,Judith White,Robert Meyer,Robert Perry,Robert Jenders,Mark McKenzie,Obadias Marquez,Christopher Still,Ernesto Fuentes,Kevin Merkes,Laura Pearlman
DOI: https://doi.org/10.1056/NEJMoa2401943
2024-07-25
Abstract:Background: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with liver-related complications and death. The efficacy and safety of tirzepatide, an agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, in patients with MASH and moderate or severe fibrosis is unclear. Methods: We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks. The primary end point was resolution of MASH without worsening of fibrosis at 52 weeks. A key secondary end point was an improvement (decrease) of at least one fibrosis stage without worsening of MASH. Results: Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group. The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons). The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42). The most common adverse events in the tirzepatide groups were gastrointestinal events, and most were mild or moderate in severity. Conclusions: In this phase 2 trial involving participants with MASH and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis. Larger and longer trials are needed to further assess the efficacy and safety of tirzepatide for the treatment of MASH. (Funded by Eli Lilly; SYNERGY-NASH ClinicalTrials.gov number, NCT04166773.).